GHRP-2 vs GHRP-6 vs Hexarelin: Which Secretagogue?

GHRP-2, GHRP-6, and hexarelin are the original growth-hormone-releasing peptides — the synthetic compounds that, in the 1990s, taught researchers there was a whole second pathway for releasing growth hormone besides GHRH. They get compared constantly in peptide forums, usually with confident claims about which one is 'best.' The honest version is more useful: these three are close cousins that all raise growth hormone through the same receptor, but they differ in two practical ways that actually matter — how much they trigger hunger, and how much they spill over into cortisol and prolactin. This piece lays out those differences from the human pharmacology that established them, and is clear about the large caveat hanging over all three.

What they all are: ghrelin-receptor secretagogues

GHRP-2, GHRP-6, and hexarelin are not GHRH analogs like sermorelin or tesamorelin. They are growth-hormone secretagogues that act at the growth hormone secretagogue receptor (GHS-R) — the receptor identified in the human pituitary and brain in the late 1990s¹ whose natural ligand, the stomach hormone ghrelin, was discovered in 1999². In other words, these synthetic peptides predate the discovery of the hormone they imitate: they were found to release GH years before anyone knew the body had its own molecule (ghrelin) doing the same thing³. That shared mechanism is why all three reliably raise GH — and also why their differences are differences of degree, not kind.

GHRP-6: the hunger one

GHRP-6's defining trait is appetite. Because it activates the ghrelin receptor strongly, it triggers the same hunger signal ghrelin itself does — and ghrelin is the body's principal hunger hormone, demonstrated to drive food intake when administered in controlled studies⁴. In practice GHRP-6 is the secretagogue most associated with a pronounced hunger surge shortly after dosing, which some users want (for bulking) and most find a nuisance. GHRP-6 raises growth hormone well, but it also raises ACTH and cortisol: in a study of GHRP-6's endocrine effects, it stimulated GH release alongside increases in ACTH and cortisol⁵. So GHRP-6's profile is 'strong hunger, real GH release, with some stress-hormone spillover.'

GHRP-2: more GH, less hunger, but cortisol and prolactin too

GHRP-2 is generally the more potent GH releaser of the pair and provokes less of the intense hunger that defines GHRP-6 — which is why it's often preferred when appetite stimulation isn't the goal. But potency comes with its own spillover. In a direct human comparison, GHRP-2 (alongside hexarelin) produced a clear rise in growth hormone but also significantly increased prolactin, ACTH, and cortisol — more so than GHRH, and through a mechanism distinct from the classic stress-hormone releasers⁶. That cortisol and prolactin rise is the trade-off: GHRP-2 pushes GH harder than GHRP-6 with less hunger, but it is not 'cleaner' on the stress-hormone axis.

Hexarelin: the most potent — and the desensitization problem

Hexarelin is the most potent GH releaser of the three, and in head-to-head human work it behaves much like GHRP-2 on the endocrine side: strong GH release accompanied by increases in prolactin, ACTH, and cortisol⁶. Its distinguishing liability is tachyphylaxis — a tendency for the GH response to diminish with repeated or continuous dosing. The desensitization question was studied directly and the picture is nuanced: short-term intranasal or oral hexarelin did not blunt subsequent GH responsiveness in one study⁷, and a review concluded that meaningful desensitization is not inevitable but can occur with sustained exposure⁸. The practical read: hexarelin hits hardest, but its effect is the one most likely to fade if used continuously, and like GHRP-2 it carries the cortisol/prolactin spillover.

Why ipamorelin is the modern answer to all three

The reason ipamorelin exists is precisely the cortisol/prolactin/hunger problem these three share. When ipamorelin was first characterized in 1998, its headline feature was that it released growth hormone with potency comparable to GHRP-6 but without the cortisol and prolactin increases of the other secretagogues⁹ — and without GHRP-6's strong appetite drive. That selectivity is the entire reason ipamorelin displaced the older GHRPs in modern use. So if you're comparing GHRP-2, GHRP-6, and hexarelin and wondering which is 'cleanest,' the honest answer is that the cleaner secretagogue is usually the next-generation one. We cover its real-world profile in ipamorelin side effects: what's actually documented and how it differs from the GHRH side of the axis in sermorelin vs ipamorelin.

The caveat that applies to all three

Here is the part the comparison charts leave out. None of GHRP-2, GHRP-6, or hexarelin is an FDA-approved drug. They were investigational compounds — extensively characterized in human endocrine pharmacology in the 1990s, which is why we can describe their GH, cortisol, prolactin, and appetite effects with real citations — but none advanced to approval, and today they trade largely as research chemicals with no manufacturer label, no quality guarantee, and no long-term human safety or outcome data. Everything documented about them is short-term, marker-based endocrine pharmacology (GH, cortisol, prolactin, hunger), not evidence that they safely deliver muscle, fat loss, or anti-aging results over time. The supply is unregulated, so what's in a vial is not assured. Treat any 'which is best' verdict as a pharmacology comparison, not a recommendation to use an unapproved compound.

The bottom line

Across the three original GHRPs, the practical differences are real but narrow. GHRP-6 is the hunger one: strong appetite drive via the ghrelin receptor, solid GH release, some cortisol spillover. GHRP-2 pushes GH harder with much less hunger, but raises cortisol and prolactin in the process⁶. Hexarelin is the most potent of all, with the same cortisol/prolactin trade-off and the added quirk of possible desensitization with sustained use⁸. The selectivity problem they share — stress-hormone and appetite spillover — is exactly what the newer secretagogue ipamorelin was designed to avoid⁹. But the overriding caveat is that all three are unapproved research compounds with only short-term marker data behind them, so 'which secretagogue' is a question about pharmacology, not a proven path to results. For the GH-peptide that actually has outcome trials, see CJC-1295 benefits: what the evidence shows, and for the full picture across this class start with our pillar guide, Sermorelin for Sleep, Recovery & Healthy Aging. If you're weighing legitimate, prescribed GH-peptide providers, we rank them in our guide to the best sermorelin providers.